Emmaus Life Sciences, Inc.
EMMA
$0.0155
-$0.0015-8.82%
| Weiss Ratings | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 6.64 | |||
| Price History | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.82% | |||
| 30-Day Total Return | -11.43% | |||
| 60-Day Total Return | 10.71% | |||
| 90-Day Total Return | -48.16% | |||
| Year to Date Total Return | 82.35% | |||
| 1-Year Total Return | -85.24% | |||
| 2-Year Total Return | -95.16% | |||
| 3-Year Total Return | -97.93% | |||
| 5-Year Total Return | -98.89% | |||
| 52-Week High % Change | -86.37% | |||
| 52-Week Low % Change | 15,400.00% | |||
| Price | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.11 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Aug 14, 2024 | |||
| 52-Week High Price (Date) | Apr 16, 2024 | |||
| Valuation | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 989.92K | |||
| Enterprise Value | 32.27M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.08 | |||
| Earnings Per Share Growth | -18.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.12 | |||
| Price/Book (Q) | -0.02 | |||
| Enterprise Value/Revenue (TTM) | 1.58 | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | 787.14 | |||
| Enterprise Value/EBIT | 1,792.94 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 162.73M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 310 214 0065 | |||
| Address | 21250 Hawthorne Boulevard Torrance, CA 90503 | |||
| Website | www.emmausmedical.com | |||
| Country | United States | |||
| Year Founded | 2000 | |||
| Profitability | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 0.08% | |||
| Profit Margin | -17.11% | |||
| Management Effectiveness | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 0.03% | |||
| Return on Equity | -- | |||
| Income Statement | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 20.43M | |||
| Total Revenue (TTM) | 20.43M | |||
| Revenue Per Share | $0.13 | |||
| Gross Profit (TTM) | 19.35M | |||
| EBITDA (TTM) | 41.00K | |||
| EBIT (TTM) | 18.00K | |||
| Net Income (TTM) | -3.50M | |||
| Net Income Avl. to Common (TTM) | -3.50M | |||
| Total Revenue Growth (Q YOY) | 9.17% | |||
| Earnings Growth (Q YOY) | 2,626.87% | |||
| EPS Diluted (TTM) | -0.08 | |||
| EPS Diluted Growth (Q YOY) | 2,140.00% | |||
| Balance Sheet | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.26M | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 9.20M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -53.78M | |||
| Current Ratio (Q) | 0.144 | |||
| Book Value Per Share (Q) | -$0.84 | |||
| Total Assets (Q) | 27.34M | |||
| Total Current Liabilities (Q) | 64.13M | |||
| Total Debt (Q) | 32.54M | |||
| Total Liabilities (Q) | 81.12M | |||
| Total Common Equity (Q) | -53.78M | |||
| Cash Flow | EMMA - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 2.50M | |||
| Cash from Financing (TTM) | -1.16M | |||
| Net Change in Cash (TTM) | -250.00K | |||
| Levered Free Cash Flow (TTM) | -146.30K | |||
| Cash from Operations (TTM) | -1.59M | |||
